Oncopro EGFR ARMS PCR Test: Advanced EGFR Mutation Detection for Lung Cancer
Introduction to EGFR Mutation Testing
The Oncopro EGFR ARMS PCR Test represents a breakthrough in precision oncology, offering highly sensitive detection of EGFR (Epidermal Growth Factor Receptor) gene mutations that are critical for guiding targeted therapy decisions in lung cancer treatment. This advanced molecular diagnostic test utilizes Amplification Refractory Mutation System (ARMS) technology combined with Real-Time PCR to provide accurate, reliable results that can significantly impact patient outcomes.
EGFR mutations occur in approximately 10-15% of non-small cell lung cancer (NSCLC) patients in the United States, particularly in non-smokers, women, and individuals of Asian descent. Identifying these specific genetic alterations is essential because patients with EGFR-mutated lung cancer often respond exceptionally well to EGFR tyrosine kinase inhibitors (TKIs), which can dramatically improve survival rates and quality of life compared to traditional chemotherapy.
What the Oncopro EGFR ARMS PCR Test Detects
This sophisticated molecular test specifically identifies mutations in exons 18 through 21 of the EGFR gene, including:
- Exon 19 deletions – the most common EGFR mutations
- Exon 21 L858R point mutations – second most frequent EGFR alteration
- Exon 20 insertions and T790M mutations
- Exon 18 G719X mutations
- Other rare EGFR mutations affecting treatment response
The ARMS PCR technology employed in this test offers superior sensitivity, capable of detecting mutations present in as little as 1% of the tumor cell population. This high sensitivity is particularly important for patients with limited tumor tissue samples or those being tested after previous treatments.
Who Should Consider EGFR Mutation Testing
Clinical Indications and Patient Profiles
The Oncopro EGFR ARMS PCR Test is recommended for:
- Newly diagnosed patients with advanced non-small cell lung cancer (NSCLC)
- Patients with adenocarcinoma histology, regardless of smoking history
- Individuals presenting with symptoms including persistent cough, chest pain, shortness of breath, or unexplained weight loss
- Patients with metastatic lung cancer requiring treatment planning
- Those who have developed resistance to previous EGFR-targeted therapies
- Non-smokers or light smokers diagnosed with lung cancer
- Women with lung cancer, particularly of Asian ethnicity
Benefits of EGFR Mutation Testing
Undergoing the Oncopro EGFR ARMS PCR Test provides numerous advantages for lung cancer patients:
- Personalized Treatment Selection: Identifies patients who will benefit most from EGFR-targeted therapies
- Improved Survival Outcomes: Patients with EGFR mutations treated with targeted therapy show significantly better progression-free survival
- Reduced Treatment Side Effects: Targeted therapies typically have fewer side effects than traditional chemotherapy
- Informed Clinical Decisions: Provides crucial information for oncologists to develop optimal treatment strategies
- Monitoring Treatment Response: Helps assess development of resistance mutations during therapy
- Cost-Effective Care: Avoids unnecessary chemotherapy in mutation-positive patients
Understanding Your Test Results
Interpreting EGFR Mutation Status
Your test results will fall into one of several categories, each with specific treatment implications:
EGFR Mutation Positive
If your test detects specific EGFR mutations (such as exon 19 deletions or L858R), you are likely to respond well to EGFR tyrosine kinase inhibitors like gefitinib, erlotinib, afatinib, or osimertinib. Your oncologist will discuss the most appropriate targeted therapy based on your specific mutation profile.
EGFR Mutation Negative
A negative result indicates that no common EGFR mutations were detected in your tumor sample. In this case, your treatment plan may focus on other targeted therapies, immunotherapy, or chemotherapy based on additional biomarker testing and clinical factors.
Insufficient Sample or Invalid Result
Occasionally, the tumor sample may not contain enough genetic material for accurate testing. In such cases, your healthcare provider may recommend obtaining a new tissue sample or considering liquid biopsy alternatives.
Test Pricing and Availability
| Test Name | Regular Price | Discount Price | Turnaround Time |
|---|---|---|---|
| Oncopro EGFR ARMS PCR Test | $308 USD | $278 USD | Sample by Monday 11 AM; Report in 4 working days |
Sample Requirements
The test requires submission of a formalin-fixed paraffin-embedded (FFPE) tissue block. The block must contain at least 10% tumor tissue and should be shipped at room temperature to ensure sample integrity.
Nationwide Testing Availability
We have diagnostic centers conveniently located throughout the United States, serving patients in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more cities. Our network of certified laboratories ensures consistent, high-quality testing standards nationwide.
Take Control of Your Cancer Treatment Today
Don’t leave your treatment decisions to chance. The Oncopro EGFR ARMS PCR Test provides the critical genetic information needed to pursue the most effective, personalized lung cancer treatment available. With our discounted price of only $278 USD and rapid 4-day turnaround, you can quickly obtain the answers that could significantly impact your treatment journey.
Ready to schedule your test? Call our dedicated oncology testing specialists today at +1(267) 388-9828 or book your appointment online. Our team is available to answer your questions and guide you through the testing process, ensuring you receive the personalized care you deserve.
Take the first step toward precision cancer care – contact us now to schedule your Oncopro EGFR ARMS PCR Test and unlock the power of targeted therapy for your lung cancer treatment.
